Publication Year: 2023
-
Real World Impact of a Blood Based Integrated Classifier on the Management of Benign Solid, Part Solid and Ground Glass Pulmonary Nodules
-
Comparison of a high specificity blood-based biomarker with FDG-PET for identifying malignant pulmonary nodules
-
Real World Efficacy Of First-Line Immunotherapy With Or Without Chemotherapy In Advanced NSCLC Stratified By Serum Proteomics
-
Use Of A Blood-Based Biomarker May Expedite Diagnosis Of Malignant Nodules By Supporting Biopsy
-
Using a Blood Biomarker to Distinguish Benign From Malignant Pulmonary Nodules
-
Impact of an integrated classifier using biomarkers, clinical and imaging factors on clinical decisions making for lung nodules
-
Assessing a biomarker’s ability to reduce invasive procedures in patients with benign lung nodules: Results from the ORACLE study
-
Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: Initial findings from a retrospective aggregate analysis of 8 clinical trials
-
Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Commercial Payer Setting
-
Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Medicare Payer Setting